A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dosed Phase II Clinical Study to Evaluate the Efficacy and Safety of LPM787000048 Maleate Extended-Release Tablets (LY03020) in Acutely Psychotic Adult Subjects With Schizophrenia
Latest Information Update: 27 Apr 2026
At a glance
- Drugs LY 03020 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Luye Pharma Group
Most Recent Events
- 08 Apr 2026 According to Luye Pharma Group media release, the first patient has been dosed in the trial.
- 31 Mar 2026 Status changed from not yet recruiting to recruiting.
- 13 Feb 2026 New trial record